Pharma Intelligence Center (PIC) - 7 Plus modules provide users a 360-degree view of the industry

1. Drugs Intelligence
药物/竞品评估

Pipeline & Marketed Drugs (from discovery)
管线及上市品种
Drug development – history of events
药物开发历史沿革及格局分析
Drug sales & consensus forecasts
药物销售及投行预测
Partnering details (Originator & Licensing)
权益变化追踪及各国情况
Merger & risk-adjusted NPV Analyzer
产品并购及风险调整的净现值分析工具
Epidemiology Database
流行病学数据库模组（覆盖430+疾病）
PTSR/Likelihood of Approval (incl. LoA alert)
临床成功/药物获批率分析 – 单药/适应症
Regulatory Milestone Tracker
注册审评里程碑
Contract Manufacturing Database
药物生产信息（生产商、厂房、代工情况）
PharmSource Reports
合同代工服务产业分析报告
Licensing Opportunity Finder (*New)
2024全新独家BD合作机会平台

2. Trials Intelligence
临床/医学调研

Clinical Trials Database
全球临床项目（覆盖435,000+）
Trial Profile with protocol data
临床项目报告分析及全面试验数据
Investigators Database
全球研究员模组及联系方式
Enrollment Data and Analytics
入组数据及分析模组
Trial Sites
全球临床选址模组
Site Coordinators
临床地点协调员模组及联系方式
Biomarker Database
生物标志物模组
Decentralized/Virtual Trials Filter Ethnicity/Race Filter
特殊检索条件优化e.g. 去中心化 / 种族
Clinical Trial Trend & CRO Reports
临床趋势白皮书及CRO报告
Trial Feasibility Planner
临床开展可行性评估工具
Clinical Trial Cost (*New)
2024全新独家临床费用数据

3. Therapeutic Analysis
疾病/市场预测

Disease Reports
疾病分析报告
Patient-based Drug Sales Forecast
基于流行病学的药物/适应症销售预测模型
Epidemiology Reports
流行病学分析报告
Epidemiology model & Patient Flow Dashboard (*New)
流行病学数据及全新Patient Flow分析模型
Competitive assessment – Drug/Indication
药物临床及商业化指标的竞争分析模型
Thematic Analysis
技术领域分析报告(e.g. ADC, CGT, IO, etc.)
Conference Organizing Tools & Reviews
会议参会计划工具及会议总结报告
Webinars and Virtual Conferences
自有分析师举办研讨会及邀请制线上会议
Model-based Sales Forecasts up to 68 Markets (*New)
通过全球医疗保健支出数据提供适应症销售预测覆盖全球68个市场国
Drug Insights (KOLs interviews)
每日独家KOL访谈报道

Alternative Data & Analytics
基础竞情及分析工具

Companies Database
公司模组，覆盖全球医药行业相关企业140,000+
Company Fillings & Financial Analytics
公司披露监听及财务数据分析
Advanced Company Watchlist
自定义公司竞情追踪创建
Build Your Own Storyboard for any Company
自定义公司尽调报告
Drug by Manufacturer Map
药物生产商地图

Deals Database & Analytics
交易模组，覆盖150万+ M&A, Capital Raising, Grants, Licensing & Partnership, Contract Service Agreements 各类型交易及分析（金额、首付款、因素etc.）
Deal Firms (Investors & Advisors)
交易生成相关企业及趋势分析
News Database
新闻模组，覆盖全球医药行业新闻60万+
Newsletter: Pharma DECODED
自定义每日新闻分析推送
Pharmaceutical Technology & Clinical Trial Arena
自有医药行业新闻媒体平台（研发&临床面向媒体平台及每月杂志）

4. Lead Sheet
业务线索/联系人

Catalyst Calendar
药物/公司/适应症 – 临床、注册、IP催化剂事件预测及追踪
Contacts** (up to 400,000)
联系人方式（包括各职能部门&C-level)
Lead Sheet planning tools and alerts
业务线索个性化设置、推送、追踪、提醒
Outsourced Insights
独家C-level访谈提供一手外包服务需求
Catalyst Monitor Reports
催化剂事件预测分析报告

*Drugs Database required 需要订阅Drugs板块
***Purchase options with or without downloads*

5. Patents Database (beta)
专利分析

Global Patents Coverage
全球专利信息覆盖
Patent trends analysis
专利注册趋势分析
Constraining Patents & Expiry
核心专利及到期分析

*Drugs Database required 需要订阅Drugs板块

AI HUB *
全新AI互动问答及工作流程优化工具
2024全新上线

6. Price Intelligence (POLI)
全球药价/市场准入/医保政策

Drug Pricing Database (80 countries)
全球药品价格数据
POLI Indicators
国家药品价格趋势及医保触达分析
POLI Insights
药价变化趋势洞察
POLI Therapeutics (cost Calculator)
平均治疗价格及治疗周期计算
IRP (International Reference Pricing) Matrix
国际参考价格评估体系
Policy &Reimbursement System Profiles
各国政策及医保系统评估
Market Access Risk Score
各国市场准入风险评估
Risk Sharing Database
风险分摊定价模型
Headline Analysis
各国热点分析包括政策及医保改革，以及HTA对药品价格影响分析

7. World Markets Healthcare
全球医疗保健支出及国别分析

Country Profile Matrix
国别医疗体系分析
Country Reports
国别报告
Expenditure and Sales Forecasts
各国医疗保健支出及各TA销售预测
Geography Ranking
国别评级（整体医药销售、人口、支出、公共/私有健康花费 etc.)
Service Bulletins
药品价格变化及新进入市场药价监控
Strategic Reports
国别市场准入洞察分析报告

Strategic Intelligence *
创新行业/产业/技术主题版面
2024全新上线

Additional purchase options

Direct Data Solutions (e.g. APIs)
Consulting
CI Trackers / Digital Landscapes
Site Survey

2025 Product Enhancements

Drugs Intelligence

2025 Enhanced Features

- 药物获批率LOA/PTSR提供自有评估参数及模型
- 单药投行销售预测提供额外sales geography – China & royalty data
- Risk-adjusted NPV模型升级，结合LOA/PTSR提供可调节在线风险可调整的净现值模型
- 靶点检索升级 Target & Boolean search及外部文献关联
- 新技术检索标签升级
- **Licensing opportunity finder 全网独家*** 跨境合作机会平台
- Regulatory Milestone 监管里程升级，全面关联专利提供核心专利到期数据及各类型特殊审评资格追踪
- Deals Analytics 交易分析升级提供交易成因分析及交易金额计算benchmark
- Companies Database 公司档案升级提供storyboard自动生成公司简报及AI智能提问，并可根据检索结果生成客户地图
- **Epidemiology & Market Size 核心优势***提供覆盖全球20个治疗领域近500适应症的流调数据（包括中国）并提供深入patient flow dashboard – 具体参考Therapeutic Analysis板块内容

板块1：药物/竞品评估 Drugs Intelligence

Global coverage of pipeline drugs, deals, news, deals and companies; marketed drugs across 20+ countries including the US, Europe, LATAM and Asia. Updated daily.

Pipeline Drugs
~96,200 pharma and biologics, discovery to pre-registration

Marketed Drugs
~ 171,800 novel, biologic, biosimilar and generics

Regulatory Milestones Tracker
Patent Expiry for ~10,600 drugs and ~ 6,600 review designations

Drug Sales & Consensus Forecast
~ 10k drugs Historical sales from 2000; eight-year analyst consensus forecast

PharmSource
Leading source for global contract manufacturing intelligence, 8K contract service provider facilities, 3k drugs by manufacturer

Assess competitive drug development landscape

Companies
Over 145,000 companies profiled including locations and subsidiaries Financial status, R&D investment and focus, etc.

Deals
1.7M Deals including M&A, licensing & partnership, financings and grants

News
Press releases and proprietary articles covering latest events and trends – over 600,000 articles

↑

Understand companies and key activities occurring across the pharma industry in real-time

Financials
Income statement, balance sheet and cash flow statements, plus financial ratios

NPV & rNPV
16-year sales forecasts; change expiry and growth assumptions

Integrated Export
Single search and export from multiple databases

Likelihood of Approval
Predict likelihood of approval and phase transition success rate of a drug - ~20,000 individual LOAs

↑

Take advantage of Analytical Tools on Pharma Intelligence Center

Epidemiology Data
Available in Drugs and linkage to Therapeutic Analysis
Over 450 indication with patient flow dashboard

Coverage - Geography

GLOBAL COVERAGE
Pipeline Drugs
News, Deals, Companies

Marketed Drugs

US	
Europe	UK
	Germany
	France
	Spain
	Italy
	Switzerland
	Belgium
Japan	
BRICS	Brazil
	Russia
	India
	China
	South Africa
Other	Mexico
	Canada
	South Korea
	Australia
	New Zealand
	Indonesia
	Israel

示例： 针对适应症及单药的Phase Transition Success Rate & Likelihood of Approval Rate

3,500+ 适应症benchmarks



查看适应症下所有品种PTSR & LoA及阶段变化impacting events



10,000+ 药物PTSR & LoA





History of Changes - PTSR/LoA

单药报告中提供对不同开发适应症的详尽模型数据

新功能示例： PTSR & LoA – Drug per indication 2.0 版本

最新更新的PTSR/LoA V2.0版本→在药物档案中Drug Profile
提供药物针对每个适应症的PTSR (v.s. 行业对比benchmarks) 以及 LoA



提供PTSR%的具体计算逻辑/考虑因素和内部Modelling中的得分

追溯PTSR/LoA的变化原因（配合sources – 例如关联特定临床试验项目及结果）
并实时因为重大事件影响而动态更新

Archive - History of Changes

Date Updated	Development Stage	Key Events Impacting PTSR/LoA	GlobalData Insights	Phase Transition Success Rate (PTSR)			Likelihood
				Previous Value	New Value	Change	Previous
07-Sep-2024	Phase III	PTSR/LoA scores from LoA V1.0 prior to LoA V2.0 model			63%		
11-Sep-2024	Phase III	Breakthrough Therapy Granted (United States)		61%	63%	2%	41%
07-Jun-2024	Phase III	Clinical Trial Result - Achieved (GDCT0372775)		49%	61%	12%	33%
		Ongoing Trial (Added) (GDCT0521464),Trial Status Changed from Ongoing to Completed (GDCT0372975)					
18-Apr-2024	Phase III	Additions of Broker forecasts		47%	49%	2%	30%
07-Sep-2023	Phase III	Orphan Drug Designation Granted (EU)		46%	47%	1%	29%
23-Mar-2023	Phase III	Fast Track Drug Designation Granted (United States)		44%	46%	2%	28%
03-Nov-2021	Phase III	Phase Transition from Phase II to Phase III			44%		
04-Mar-2021	Phase II	Clinical Trial Result - Inconclusive		50%	50%	10%	14%
		Trial Status Changed from Ongoing to Completed					
03-Oct-2020	Phase II				50%		

新功能示例： 药物靶点直接链接外部文献











新功能示例： 投行单药销售预测可view by indication, target, sales region 并增加Geography – China Sales Specific 以及Royalty Data



全球合作TOP brokers 50+ 每季度提供单药销售预测更新 – 评估靶点及地区市场潜力



新增中国区投行/券商销售预测 每个季度更新并查看投行列表



示例： 结合投行单药销售预测 + 自有模型LoA (药物获批率分析) - 制定在线可调节risk-adjusted NPV

FEATURE

- Enhancement of the NPV tool via the addition of risk-adjusted calculations.
- Incorporation of risk-adjusted trial costs using phase durations and PTSR, plus risk-adjusted revenue forecasts using LoA

BENEFIT

- Perform analyses by compiling multiple risk-adjusted forecasts/NPVs by drug or company.
- Compare non-risk adjusted forecasts with proprietary, LoA-risk-adjusted forecasts, which represent a more realistic valuation.

VALUE

- Identify investment targets based on robust NPV analyses.



示例： 药物检索维度包括药物技术及持续更新的创新科技100+



示例： Deals Analytics

See Deal Results from Dashboard 交易检索结果呈现界面



See Deal Results from All Deals List 交易列表 - 支持个性化呈现及导出



See Deal Results from Deal Profile 交易档案，提供详细交易细节、金额、可比交易、发生双方及原始渠道



See Deal Results from Deals Analytics 交易分析在线互动工具 → 图像数据提供交易机会、交易金额趋势、交易潜在发生方向 … etc.



示例：Storyboard – 关联公司界面自动生成公司简报



独家跨境合作工具：Licensing Opportunity – 让您的out interest被潜在买家看到并直接通过平台对接

通过全球覆盖的管线品种及海内外庞大的BD用户网络，我们将医药智库赋能全球跨境合作交易平台



支持自定义检索有意向out-licensing assets并可进入药物报告中查看细节



独家渠道收录
out-licensing interest
确保真实准确高效

支持通过PIC portal – My licensing Opportunities对自家品种的授权意向进行实时编辑，并可授权让有意向的parties与您直接联系



我们将持续优化工具扩大授权意向信息量
并结合Lead Sheet – Contacts让双方高效对接

若希望自己的意向被看到，请与我们联系

Other Key Product Enhancements – Drugs Intelligence

Enhanced Email Alert Formats

邮件推送格式优化

- Easier to digest format to clearly display change in a more tabular format
- Provide some key insight within the email
- Address regular client complains (Avantor, iOnctura, TFS, Alira, etc.

Alert Title: Ongoing & Planned trials : GlobalData Pharma Intelligence Center D

Alerts Summary	
New Trials	1
Trial Updates	3

Date	Trial Title	Trial Identifier	Update Details	
			Previous	Current
18-Aug-23	A Clinical Study of SP-04 in Chemotherapy Induced Peripheral Neuropathy	GDCT0396742; GDC30024942		
18-Aug-23	A Clinical Study on Almitrine Bismesylate for Treating COVID-19	GDCT0389525; GDC30024022	Coronavirus Disease 2019 (COVID-19)	Coronavirus Disease 2019 (COVID-19); Hypoxemia

Private Company Valuation

私有公司估值功能优化

- Create a data science model based on historical data and our equity stake filter to estimate the value of private companies
- Support on pharma valuations

Row Labels	Average of Deal Value (US$m)	Average of Acquired Stake (%)	Count of Acquired Stake (%)
Private Equity	171.2499866	43	50
Direct Investment	67.71157774	13	6
Institutional Buy-out (E	1005.378867	85	16
Leveraged Buy-out (LB	1065.8652		
Management Buy-in (M	125		
Management Buy-out (	1073.569	95	1
Secondary Buy-out	924.6557471	36	4
(blank)	169.8882767	21	23
Grand Total	171.2499866	43.2376	50

Logic Outline	
1)	For private companies, look at P/E Deals in the past 7 years. If Acquired Stake is available for any deal (take the most recent), Company Value: Deal Value * 100 / Acquired Stake %
2)	For private companies, if there are any P/E deals in the past 10 years, assume they are PE owned. If Deal Level 3 = Direct Investment, IBO, or Secondary Buy Out, assume the average Acq
3)	Same as above, but if Deal 3 <> options above, then use the 43% acquired stake

Ideas to Explore	
a)	Calculate option 1 above for a sample of companies where the acquired stake is available
b)	Collect data on: Deal Stage (Lead), Company Drug Count, Company HQ Country, any other attributes that may correlate with the value of the company

Search & Export Enhancements

自定义导出格式优化

- Work with software to find quicker solutions for:
- Smarter searches within databases and global searching
- Save customize results template (like POLI)
- Increase Export limits
- Save custom export templates
- Boolean Searches throughout

Drug Scientific Conference Coverage Expansion

学术会议及早期管线捕捉优化

- Increase the coverage of planned scientific conferences
- Enhance the database integrity by coverage of new drugs and updates
- Focus on early-stage drug coverage
- Provide exclusive insight into new research, clinical trial results, and advancements in drug development

Other Key Product Enhancements – Drugs Intelligence

Drug Search Enhancements

靶点及机制标签检索优化

- Expand Molecule and Descriptor Tags
- Standardization of target taxonomy
- Additional data points such as UniProt, Entrez, Ensemble, and HUGO IDs and hyperlinking these
- Enhancing the global search for critical taxonomies
- Addition of smart searches within a database to cover all attributes

Companion Diagnostics

PIC数据库中增加CD覆盖



- CDx provides insights into the market landscape by identifying diagnostic needs for specific therapies
- Provides Competitive landscape by analyzing which drugs are paired with specific diagnostics.
- Ensures GlobalData maintains a competitive edge over competitors

Antigen & Adjuvant Search

优化对上市疫苗品种的检索条件



- Provide Antigen and Adjuvant details for all Marketed vaccines
- Ensure GlobalData maintains a competitive edge over competitors

Reference Listed Drug (RLD) & First Generic Approval

对所有仿制药提供RLD参考



- Provide RLD mapping for all generic drugs with innovator
- Provides Competitive landscape by analyzing RLDs and existing generic versions.
- RLD can be utilized as a benchmark for conducting BE studies required for generic drug approval.

Other Key Product Enhancements – Patents (beta stage)

Patents Analytics planned features

> Patent Analytics – Anticipated Expiry Dates



- Anticipated Expiry Date Details and Anticipated expiry dates for patents for all the authorities
- Refinement and analytics based on patent expiry dates

> Patent Analytics – Life State



- Patent state display in refinment to show current patent state e.g., Active, In-active or Expired/ Terminated
- Patents Tagging for Media IC
- Theme, IC and sector tagging updates

> Patent Analytics – Patent Term Extension and Adjustment Flags

- Patent Term extension and adjustment flags for patents
- SPC/PTE and Paediatric Extensions
- TD and PTA information for US patents

> Patent Analytics – Sector and Theme Tagging enhancement

1 Enhance Theme Tagging
- Target to improve accuracy and patent coverage for themes approved for patents.

2 Enhance Sector Tagging
- Enhance sector tagging for uncovered nodes and enhance patent coverage for existing nodes.

3 Enhance IC Tagging
- Update IC tagging logic to improve accuracy and increase coverage

Note: Features are yet to be approved for front end development. Patents are being updated in backend currently to reflect the planned features

示例：专利分析板块*（测试阶段）

Patent Analytics

FEATURE

Identify global patenting and technology trends with GlobalData's Patent Analytics.

Access **patent bibliographic information and analysis**, including full specifications and legal event notifications from US and EP. **GlobalData's Patent Analytics** also provides an intelligent **dashboard** covering **patent intelligence** available by sector, theme, company or geography providing focused insight.

BENEFITS

Utilize Patent Analytics to gain rapid intelligence into the innovation landscape and make better investment decisions.

- Identify and monitor **key innovation trends**, the **most innovative companies**, potential partners, and **IP portfolios for acquisitions**
- Uncover **competitive innovation strategies to distinguish your approach.** Identify **critical IP investments, competitor patent activity, and new product development strategy** and determine **potential threats and opportunities**
- **Invest wisely** with the **right IP intelligence** at your fingertips. **Recognize the emerging technologies, start-ups, and tech areas attracting heavy R&D and patenting activity** that will have an impact on your sector
- Monitor **critical trends in IP protection** and most **heavily IP protected sectors & themes**

VALUE

- **Prioritize investments** by predicting company valuations and **tracking innovation trends**
- Reshape and **Refresh Your Product Portfolio** by tracking technology development across geographies
- **Minimise time spent tracking patent sources**, access GlobalData's Patent Analytics, an all-in-one platform



101
Countries tracked

60k+
Company portfolios

11.5M+
Published Patent records

Trials Intelligence

2025 Enhanced Features

- Clinical Trial Cost Estimator 全新临床费用计算工具，提供已完成临床项目费用数据以预测即将开展临床的可能花费
- Enrolment data per country 提供国家/地点维度入组数据
- Feasibility Planner 在线临床可行性评估工具
- **Clinical results comparator 全新工具*** 可视化对比某个适应症的全部最新药效及安全性数据dashboard
- 优化临床检索标签，包括Boolean logic, Line of therapy, etc.
- 全面优化临床试验报告 – 试验结果呈现及渠道覆盖

Clinical Trials Intelligence – 2025 Snapshot

Global coverage of Clinical Trials Intelligence; 250+ clinical trial registries and 200+ conferences tracked worldwide; tagging of decentralized/virtual trials and enrollment by race/ethnicity. Updated daily.



示例：Feasibility Planner – 对您即将开展的临床进行前期规划

创建任意想开展/调研的临床Planner e.g. CKD PIII in USA 在线评估、甄选、追踪、提醒及推送可比临床，助力您临床开展规划、甄选、执行全过程

输入任何条件进行临床Planner创建 –
通过Competitive Activity了解现临床开发情况



通过Benchmark Model了解
该Planner条件下所有临床的开展数据及分析



根据Recommended Investigators评分推荐合适的PI



直接关联PI profile对背景进行全面查看

允许Track任何PI的临床开展/入组/申报情况

示例：Enrolment Data & Analytics – 分析不同适应症不同国家的入组效率

入组模组提供数据界面及分析界面：对适应症不同临床阶段、不同临床状态的入组情况进行动态分析

Enrollment Data

	Number of Trials	Mean	Median
No. of Subjects Planned	55	162	90
No. of Subjects Enrolled	39	121	60
No. of Sites	53	46	22
Enrollment Efficiency (%)	38	88.54	100.00
Enrollment Period (in Months)	49	27.86	24.70
Trial Duration (in Months)	56	39.84	37.15
Subjects/Site	53	11.15	4.50
Subjects/Month	49	11.61	3.15
Subjects/Site/Month	46	1.73	0.38

Search Result Timeline View

1 - 25 of 56 Customize Tables Export Refresh Select All Page 1 of 3 Previous Next Go to page 25 Results

Select	Trial Title	Trial Identifier	Study Design	Trial Duration (in Months)	Treatment Period (in Months)	Endpoint Status	No. of Sites	Enrollment Rate Parameters		
								Subjects/Site	Subjects/Month	Subjects/Site/Month
☐	Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-converting Enzyme (ACE) Inhibitor	GDCT0091274	Controlled; Open-label; Randomized; Single-centered; Treatment	75.87	60.00	Achieved	1	60.00	3.78	3.78
☐	A Study on the Efficacy and Safety of Mizoribine in Patients with IgA Nephropathy	GDCT0227470	Active control; Multi-centered; Parallel Assignment; Randomized; Single Blind; Treatment	31.47	0.03	Achieved	8	12.38	3.15	0.39
☐	Oral Treatment with PL-56 in Patients with IgA Nephropathy - An Explorative Study	GDCT0089458	Exploratory; Multi-centered; Nonrandomized; Open-label; Single Group Assignment; Treatment; Uncontrolled	39.57	9.00	Achieved	3	5.33	0.56	0.19
☐	Effects of Mycophenolate Mofetil (MMF) on Anti-HLA (Human Leukocyte Antigen) Antibody Levels in Patients Awaiting Cadaveric Renal Transplant	GDCT0064149	Nonrandomized; Open-label; Single Group Assignment; Single-centered; Treatment	30.73	14.07	Inconclusive	1	45.00	2.70	2.70



包括 Enrollment Efficiency, Rate, Drivers数据分析各国数据对比



2024年新增工具：Clinical Trial Cost 临床试验费用估算

Gain insights from historical trial cost estimates for efficient resource allocation, informed trial planning, and streamlined drug development across therapy areas

Feature

- Provides estimates of clinical trial costs for historical trials based on estimated or actual dates
- Cost data is included into trial profile, integrated results and results analytics of clinical trials

Benefits

- Allows to get an estimate of clinical trials costs
- Facilitates cost comparison across therapy areas and trials
- Provides cost visibility into clinical trial trends over time

Value

- Utilizing trial cost estimates empower strategic resource allocation for informed trial planning
- Trial cost data guides efficient drug development and expanding treatments into new or existing therapy areas efficiently



Other Key Product Enhancements – Clinical Trials Intelligence

Boolean Searching

临床板块检索条件设定优化



- Effectively filter relevant trials matching the requirements.
- Complex queries can be quickly generated by robust Boolean search panel dynamics (AND, OR, NOT options)

Trial Timeline

增加临床时间周期坐标优化临床更新追踪、时间安排及设计优化



- **Track trial date changes** for informed decision-making.
- **Benchmark timeline data** for efficient planning, risk mitigation, and performance analysis.
- **Optimize trial planning** to reduce costs and maintain budgets.

Line of Therapy

临床设计方案检索条件优化



- Line of Therapy data assists in targeted trial design for specific patient population
- Provides insights into treatment pathways
- Trial level Line of Therapy analysis helps in benchmarking therapy performance against competitors at each treatment line

Country-level Enrollment

提供临床入组/国家统计数据模型



- Provide insights regarding country-specific enrollment in a trial.
- **Client requirement:** Most of the CRO clients are looking for this level of data which is a key data set for effective trial planning.
- **Competitive advantage:** Helps us to uniquely position us to support clients in trial planning.

New Product Offering – Disease-specific Clinical Results Comparator

Using an intuitive dashboard, quickly generate asset comparisons and charts based on clinical differentiation

FEATURE

- Excel-based efficacy and safety data obtained from multiple sources, e.g., conferences, GlobalData's Pharma Intelligence Center, peer-reviewed journals, clinicaltrials.gov
- Interactive dashboard for ***indirect comparison*** of drug efficacy and safety

BENEFIT

- Allows for quick generation of indirect comparison charts for the assessment of clinical differentiation of assets

SERVICE

- Updates to the tool following new data publications (4X/year)
  - Major updates following new data reported at conferences
  - Additional updates after key clinical trial results reporting
- Support on the tool's functionality

ADDITIONAL SERVICES

- Tailored support/deliverables by analysts with disease expertise
- Additional custom deliverables
- Versions for other diseases on a custom basis



New Product Offering – Disease-specific Clinical Results Comparator

Efficacy & Safety Comparisons



New Product Offering – Disease-specific Clinical Results Comparator

Efficacy and Safety Endpoints for Comparison





GlobalData SAMPLE

New Product Offering – Disease-specific Clinical Results Comparator

Drug and Trial Attributes for Refining Trial Selection for Results Comparison

Selection using key drug and trial attributes

GlobalData SAMPLE

Therapeutic Analysis

2025 Enhanced Features

- Patient flow dashboard per indication
- Expanding epidemiology coverage – 450+ indications
- Pipeline clinical & commercial analysis with KOLs comments
- Marketed treatments forecast, SWOT with KOLs comments
- Treatment algorithm with clinical guidance
- R&D innovation strategies with target analysis
- Up to 68 markets with 10 yrs forecast
- Broaden coverage of scientific conferences – 300+ trackers

Therapeutic Analysis Module: 2025 Snapshot

15 distinct product lines

Market Analysis Reports and Forecasts
In-depth disease market analysis across relevant geographies with >210 granular forecasts

Rare/Niche Disease Reports and Forecasts
Market analysis, incl. unmet needs analysis and forecasts for ~40 rare/niche diseases

Cell & Gene Therapy (CGT) Reports
Analysis and forecasts of CGTs across a range of therapy areas incl. oncology, hematology, CNS, ophthalmology, dermatology, respiratory

Report and Forecast Updates
Reflecting market-impacting changes to the competitive environment in a disease market

Conference Program Trackers (renamed from Conference Organizing Tools)
Interactive Excel workbook outlining clinical and commercial activity for medical congresses

Landscape Overview Reports (renamed from Competitive Landscape Reports)
Visual, data-driven analyses of ~170 diseases covering drugs, trials, deals, P&R, future outlook

68-Market Forecasts
Country- and indication-specific forecasts

Modality-focused Reports
Analyses of high-interest industry-relevant topics

Webinars and Virtual Conferences
Invitation-only presentations by our in-house experts covering hot topics, with analyst Q&A

Forecast Model
Granular patient-based disease forecasts with interactive patient flow charts

Conference Reviews
Insightful coverage of key US and EU medical conferences

Therapy Influencers
~1,600 global digital influencers covering major therapy areas

Epidemiology Reports and Forecasts
Industry-leading commercial epi forecasts for 445+ indications and >700k sub-populations

Expert Insights
Insights produced by disease experts covering market-relevant topics, supported with data and primary research

Global Ads Database
Database of > 183,500 OTC drug advertisements across therapy areas

Notes: *Numbers refer to year-end 2024 coverage. Updated as of December 10, 2024*
P&R = pricing and reimbursement

Primary research driven disease analysis report and/or model or content

示例： Therapeutic Analysis 疾病领域分析报告及模型发布计划, 2025发布计划另见附件

2024 Plan

~140 reports and 20 conference planners planned for 2024

- 49 Major Market Analysis and Forecast report and models
- 7 Opportunity Assessment and Forecast reports
- 19 68-Market Analysis and Sales Forecast reports
- 5 Report and Forecast Model updates
- 55 Competitive Landscape reports
- 20 Conference Organizing Tools
- 6 Cell Therapies Market Assessment reports

CVMD

- GLP1-s in T2D and Obesity+**§
- Osteoporosis+**§
- Chronic Kidney Disease+**§
- Type 1 Diabetes+**§
- Heart Failure*§
- Adrenoleukodystrophy (X-ALD)+^¥
- Acute Coronary Syndrome◊
- Focal Segmental Glomerulosclerosis (FSGS)+^◊
- Glycogen Storage Disorders (GSD)+◊
- Hyperlipidemia+◊

Neurology

- Attention Deficit Hyperactivity Disorder (ADHD)¥
- Amyotrophic Lateral Sclerosis (ALS)^¥
- Migraine**§
- Alzheimer's Disease**§
- Parkinson's Disease**§
- Cell & Gene Therapies in CNS Disorders+‡
- Spinal Muscular Atrophy^¥
- Opioid Use Disorder¥
- Schizophrenia*
- Friedreich Ataxia+^◊
- Frontotemporal Dementia+^◊
- Hepatic Encephalopathy+^◊
- Limb girdle Muscular Dystrophies (LGMD) +^◊
- MELAS Syndrome+^◊
- Multiple System Atrophy+^◊
- Neurofibromatoses Type+^◊
- Progressive Supranuclear Palsy+^◊
- Rett Syndrome+^◊
- Spinal Cord Injury+◊
- Tay-Sachs Disease+^◊

Immunology

- Bronchiectasis*¥
- Alopecia Areata**
- COPD**§
- Asthma**§
- Psoriatic Arthritis**§
- Atopic Dermatitis**§
- Plaque Psoriasis*§
- Cell & Gene Therapies in Dermatology+‡
- Cell & Gene Therapies in Rheumatology+‡
- Cell & Gene Therapies in Gastrointestinal Diseases+‡
- Duchenne Muscular Dystrophy (DMD)^*¥
- Acute on Chronic Liver Failure Disease (ACLF)+◊
- Alcoholic Hepatitis+◊
- ANCA glomerulonephritis+^◊
- Androgenetic Alopecia+◊
- Celiac Disease◊
- Chronic Spontaneous Urticaria (CSU)+◊
- Dystrophic Epidermolysis Bullosa+^◊
- Familial Adenomatous Polyposis+^◊
- Primary Sclerosing Cholangitis+◊
- Prurigo Nodularis+◊

Oncology

- Multiple Myeloma^**
- Non-Small Cell Lung Cancer (NSCLC)**
- HER2-Positive Breast Cancer**
- B-Cell Non-Hodgkin's Lymphoma**
- Bladder Cancer**
- Prostate Cancer**
- HER2-Negative Breast Cancer**
- Head and Neck Cancer (HNSCC) **
- Cell & Gene Therapies in Hemophilia A & B+^‡
- Triple-Negative Breast Cancer (TNBC) ◊
- Chondrosarcoma◊
- Soft Tissue Sarcoma+^◊
- Esophageal Cancer^◊
- Uveal Melanoma+^◊
- Myelodysplastic Syndromes (MDS)^◊
- Melanoma*
- Glioblastoma Multiforme (GBM)^*
- Antibody-Drug Conjugates (ADC)+δ
- Pancreatic Cancer (PDAC)^¥

Infectious Diseases

- Methicillin-Resistant Staphylococcus aureus (MRSA)+**§
- Human Immunodeficiency Virus (HIV)+**§
- Sepsis**§
- Human Papillomavirus (HPV)+**§
- Nontuberculosis Mycobacteria*¥
- Epstein–Barr Virus (HHV-4) Vaccines+◊
- Gonorrhea+◊
- Hepatitis B+◊
- Hepatitis C◊
- Invasive Candidiasis+◊
- Mycobacterium Tuberculosis+◊
- Rabies Vaccines+◊

Ophthalmology

- Glaucoma+**§
- Cell & Gene Therapies in Ophthalmology+‡
- Fuchs Endothelial Corneal Dystrophy (FECD)+^◊
- Presbyopia+◊
- Retinitis Pigmentosa+^◊
- Uveitis¥

Gender Health

- Female Infertility+**§
- Dysmenorrhea+◊
- Hormone Replacement Therapy+◊
- Polycystic Ovarian Syndrome (PCOS)+◊
- Uterine Leiomyoma (Uterine Fibroids)+◊

Analysis: – Conference Organizing Tool (~20 planned from this list)

Conference	Conference Website	Base Plan	Actual/Forecast		Therapy Area
European Crohn's & Colitis Organisation (ECCO)	ECCO	Feb-24		Feb-24	Immunology
American College of Cardiology (ACC)	ACC	Mar-24		Mar-24	CVMD
American Academy of Dermatology (AAD)	AAD	Feb-24	Q1	Feb-24	Immunology
16th International Congress on SLE (LUPUS 2024)	LUPUS 2024	Mar-24		Feb-24	Immunology
International Conference on Alzheimer's & Parkinson's Disease (AD-PD)	AD-PD	Mar-24		Feb-24	Neurology
Digestive Disease Week (DDW)	DDW	Apr-24		Apr-24	Immunology
American Academy of Neurology (AAN)	AAN	Apr-24		Mar-24	Neurology
European Society of Clinical Microbiology and Infectious Diseases (ECCMID)	ECCMID	Apr-24		Apr-24	ID
European League Against Rheumatism (EULAR)	EULAR	May-24		May-24	Immunology
American Society for Clinical Oncology (ASCO)	ASCO	May-24	Q2	May-24	Oncology
European Hematology Association (EHA)	EHA	May-24		May-24	Oncology
American Thoracic Society (ATS)	ATS	May-24		May-24	Immunology
European Association for the Study of the Liver (EASL)	EASL	Jun-24		Jun-24	Immunology
Congress of the European Academy of Neurology (EAN)	EAN	Jun-24		Jun-24	Neurology
American Diabetes Association (ADA)	ADA	Jun-24		Jun-24	CVMD
European Society of Cardiology (ESC)	ESC	Aug-24		Aug-24	CVMD
European Respiratory Society (ERS)	ERS	Aug-24	Q3	Aug-24	Immunology
European Association for the Study of Diabetes (EASD)	EASD	Sep-24		Sep-24	CVMD
American College of Gastroenterology (ACG)	ACG	Oct-24		Oct-24	Immunology
United European Gastroenterology Week (UEGW)	UEGW	Oct-24		Oct-24	Immunology
European Academy of Dermatology & Venerology (EADV)	EADV	Oct-24		Oct-24	Immunology
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)	ECTRIMS	Oct-24		Oct-24	Neurology
European Society for Medical Oncology (ESMO)	ESMO	Oct-24		Oct-24	Oncology
American Academy of Ophthalmology (AAO)	AAO	Oct-24	Q4	Oct-24	Ophthalmology
ID Week	ID Week	Oct-24		Oct-24	ID
American Heart Association (AHA)	AHA	Oct-24		Oct-24	CVMD
American Association for the Study of Liver Disease (AASLD)	AASLD	Nov-24		Nov-24	Immunology
American College of Rheumatology (ACR)	ACR	Nov-24		Nov-24	Immunology
American Society of Hematology (ASH)	ASH	Dec-24		Dec-24	Oncology

示例：疾病领域分析模型 Therapeutic Analysis – Epi Forecast Model 最全面详实的流行病学数据覆盖



Patient Flow & 最新治疗方案分析



各国流行病数据对比模型

单独国家流行病数据模型底层数据披露

流调板块覆盖446个适应症UP TO 68国家 持续增加

示例：疾病领域分析模型 Therapeutic Analysis – Patient-based Forecast Model

基于病患用药及独家访谈调研的深度药物评估及估值模型

管线品种全面梳理及SWOT分析

品种专家看法：KOL访谈及医生用药调研

品种市场预测：基于流行病学的治疗药物各国销售预测模型



覆盖8个主要市场国包括中国



品种评估：临床及商业化指标

开发品种shortlist及是否交易列表



基于各国医疗保健支出数据，提供UP TO 68个市场国疾病市场潜力预测

示例：疾病领域分析报告 Therapeutic Analysis – 最可视化PPT格式产业/疾病分析报告

适应症竞争格局分析小报告





疾病分析报告PPT及下载编辑格式

技术产业分析报告





疾病分析报告PDF及在线查看格式

会议报告

参会计划工具

New Feature: 68-Market Sales Forecast Extrapolation

- Increases number of markets in GlobalData's sales forecasts from **7-10** major markets (patient-based forecasting) to **68** (sales forecast extrapolation)
- Leverages data on pharmaceutical sales and drug availability from **GlobalData's World Markets Healthcare (WMH) & POLI databases**
- Includes topline sales forecasts across numerous regions – **Africa, APAC, Europe, LATAM, Middle East, and North America**

Access topline, disease-specific sales data for an additional 58-61 markets

Compare region-and indication-specific market shares for branded, biosimilar, and generic products

Review sales forecasts from around the world in a single Excel sheet

Build better R&D and investment strategies using indication-specific sales projections from across key emerging markets

Utilize GlobalData's unlocked forecasts for scenario planning

New Product Offering: Conference Organizing Tool for Conferences Attended or Covered by GlobalData

FEATURE

- Leverage GDRC resource to produce a greater number of conference planners – a key product from the CI Trackers portfolio with positive feedback – for medical conferences covered/attended by R&A Team
- Product to be made available to subscribers to the Therapeutic Analysis module and under CI Trackers portfolio on the PIC

BENEFIT

- Produce ~25 organizers a year – increasing the breadth of deliverables in the Therapeutic Analysis Module – a further enhancement to the Module

VALUE

- Allow GD to develop a USP vs. competing vendors that provide this type of product (e.g. Larvol) given the breadth of information that in the Therapeutic Analysis Module



Analysis: – Conference Organizing Tool (~20 planned from this list)

Conference	Conference Website	Base Plan	Actual/Forecast		Therapy Area
European Crohn's & Colitis Organisation (ECCO)	ECCO	Feb-24	Q1	Feb-24	Immunology
American College of Cardiology (ACC)	ACC	Mar-24		Mar-24	CVMD
American Academy of Dermatology (AAD)	AAD	Feb-24		Feb-24	Immunology
16th International Congress on SLE (LUPUS 2024)	LUPUS 2024	Mar-24		Feb-24	Immunology
International Conference on Alzheimer's & Parkinson's Disease (AD-PD)	AD-PD	Mar-24		Feb-24	Neurology
Digestive Disease Week (DDW)	DDW	Apr-24	Q2	Apr-24	Immunology
American Academy of Neurology (AAN)	AAN	Apr-24		Mar-24	Neurology
European Society of Clinical Microbiology and Infectious Diseases (ECCMID)	ECCMID	Apr-24		Apr-24	ID
European League Against Rheumatism (EULAR)	EULAR	May-24		May-24	Immunology
American Society for Clinical Oncology (ASCO)	ASCO	May-24		May-24	Oncology
European Hematology Association (EHA)	EHA	May-24		May-24	Oncology
American Thoracic Society (ATS)	ATS	May-24		May-24	Immunology
European Association for the Study of the Liver (EASL)	EASL	Jun-24		Jun-24	Immunology
Congress of the European Academy of Neurology (EAN)	EAN	Jun-24		Jun-24	Neurology
American Diabetes Association (ADA)	ADA	Jun-24		Jun-24	CVMD
European Society of Cardiology (ESC)	ESC	Aug-24	Q3	Aug-24	CVMD
European Respiratory Society (ERS)	ERS	Aug-24		Aug-24	Immunology
European Association for the Study of Diabetes (EASD)	EASD	Sep-24		Sep-24	CVMD
American College of Gastroenterology (ACG)	ACG	Oct-24	Q4	Oct-24	Immunology
United European Gastroenterology Week (UEGW)	UEGW	Oct-24		Oct-24	Immunology
European Academy of Dermatology & Venerology (EADV)	EADV	Oct-24		Oct-24	Immunology
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)	ECTRIMS	Oct-24		Oct-24	Neurology
European Society for Medical Oncology (ESMO)	ESMO	Oct-24		Oct-24	Oncology
American Academy of Ophthalmology (AAO)	AAO	Oct-24		Oct-24	Ophthalmology
ID Week	ID Week	Oct-24		Oct-24	ID
American Heart Association (AHA)	AHA	Oct-24		Oct-24	CVMD
American Association for the Study of Liver Disease (AASLD)	AASLD	Nov-24		Nov-24	Immunology
American College of Rheumatology (ACR)	ACR	Nov-24		Nov-24	Immunology
American Society of Hematology (ASH)	ASH	Dec-24		Dec-24	Oncology

POLI

药物商业化黄金标准方案

2025 Enhanced Features

- 药价数据全面整合药物报告
- 自定义呈现标签、导出形式、在线分析格式
- 检索结果的三种呈现形式：单个产品，品牌情况，治疗费用
- **Medicine Price Prediction (MPP):** Forecast price changes of medicines from time to launch until years after generics/biosimilars are on the market. (To be planned)

Price Intelligence (POLI) 全球药价及市场准入整合方案

Understand the price-setting and reimbursement mechanisms in various countries.

- Plan your launch-sequencing strategy based on global international reference pricing and post-launch price adjustment rules. 根据全球国际参考定价(IRP)和上市后价格调整规则规划上市顺序战略。
- Find out the latest payer attitudes towards cost-effectiveness evaluations and use that knowledge to shape clinical development programs and reimbursement filings. 了解支付方对成本效益评估的最新态度，并利用这些知识制定临床开发计划和报销申请。
- Optimize market entry strategy and launch sequence based on the experience of similar products in various markets. 根据同类产品在不同市场的经验，优化市场进入策略和上市顺序。
- Prepare for HTA and reimbursement submissions by aligning time-line expectations with updated analytics and adapting your filings accordingly. 根据最新分析结果调整时限预期并相应调整申报材料，为提交 HTA 和报销申请做好准备。

Price Intelligence (POLI) Subscription Service from GlobalData

The service includes five sections, including qualitative and quantitative data. It is accessible via GlobalData's platform or via API data feeds



Bringing together our P&R market intelligence with drug pricing data we can unlock additional strategic insights:

- Track price history fluctuations and identify key pricing events links
- Forecast future price swings and opportunities by analysing trends and market events
- Understand market sensitivity and adjustment speed to market changes (i.e., HTA decisions).

** A standardized, quarterly-updated Excel repository of International Reference Pricing (IRP) that can be uploaded into simulation tools is available at an additional cost*

案例分析：偏头痛药物定价准入分析

POLI板块覆盖全球一百万+药物（原研、化药仿制药、生物类似药）
80个国家药品价格（出厂、批发、零售）
输入generic name or brand name均可，并可进一步界定上市国家、ID编号、剂型、剂量、获批流程、医保状态等等

e.g. Rimegepant 药价查询：除了单独进入POLI板块对药物进行查询之外，现POLI数据整合于药物报告中，可以直接查看药物各国各类药价信息，并关联POLI板块进一步查看相关细节





案例分析：偏头痛药物定价准入分析

在线自定义管理呈现内容，多种导出排列形式，并可在线进行直观图像分析包括药物各国医保/定价触达时间对比、该药物相关所有HTA及影响分析、药品上市顺序等等

Drug Pricing (POLI) & HTA – Results

Refine Search | Related Tools and Platforms | My GlobalData Tools

Your Refinements | Generic Name: RIMEGEPANT | Currency: USD

Note: Click on National Drug ID link to get access to the Drug Information page which includes IRP analytics and price history.

Enhanced comparative visualization is available by selecting relevant rows and clicking Comparative Analytics.

1 - 25 of 74 | Export | Result Analytics | Comparative Analytics | Manage Columns | Currency: USD - United State | Page 1 of 3 | Previous Next | Go to page 1 | 25 Results

Therapy View	National Drug ID	Drug Geography / Region	Brand Name	Source	Price Date	Ex-manufacturer Price (LCU)	Wholesale Price (LCU)	Retail Price (LCU)	International Drug ID	Dosage Form	Number of Units	Strength	Strength Comment	Volume
Yes	587729	Sweden National	VYDURA	Dental and Pharmaceutical Benefits Agency (TLV)	20 Feb 2025	SEK 2,677.78 →	SEK 2,749.44 →	SEK 2,866.43 →	EU/1/22/1645/003	ORAL LYOPHILISATE	16	75 MG	75 MG	
Yes	050080011	Italy National	VYDURA	CODIFA - Pharmaceutical Informer	20 Feb 2025	EUR 40.41 →	EUR 45.24 →	EUR 66.35 →	EU/1/22/1645/001	ORAL LYOPHILISATE	2	75 MG	75 MG	
Yes	W69731001-CANAMED	Romania National	VYDURA	Ministry of Health (CANAMED Main List)	20 Feb 2025	RON 201.24 →	RON 221.36 →	RON 270.24 →	EU/1/22/1645/001	ORAL LYOPHILISATE	2	75 MG	75 MG	
Yes	444921	Sweden National	VYDURA	Dental and Pharmaceutical Benefits Agency (TLV)	20 Feb 2025	SEK 1,338.29 →	SEK 1,374.72 →	SEK 1,457.34 →	EU/1/22/1645/002	ORAL LYOPHILISATE	8	75 MG	75 MG	
Yes	534961	Sweden National	VYDURA	Dental and Pharmaceutical Benefits Agency (TLV)	20 Feb 2025	SEK 333.67 →	SEK 343.68 →	SEK 400.52 →	EU/1/22/1645/001	ORAL LYOPHILISATE	2	75 MG	75 MG	
Yes	W69731002-CANAMED	Romania National	VYDURA	Ministry of Health (CANAMED Main List)	20 Feb 2025	RON 837.76 →	RON 867.76 →	RON 984.01 →	EU/1/22/1645/002	ORAL LYOPHILISATE	8	75 MG	75 MG	
Yes	72618-3000-02	United States National	NURTEC	Elsevier Gold Standard	19 Feb 2025	USD 1,028.99 →	USD 1,234.79 →		EU/1/22/1645/002	ORAL LYOPHILISATE	8	75 MG	75 MG	







示例：自定义导出选项，可以包括药物在所有上市国家信息、医保情况、药价（出厂、批发、零售）以及可以选择药价变化历史 up to 10 yrs, HTA 对于药品价格变化影响，以及therapy view – 药物结合治疗周期用药的销售预测



案例分析：偏头痛药物定价准入分析

检索结果表格：**1. 点击每个产品的unique ID: National Drug ID**



检索结果表格：1. 点击每个产品的unique ID: National Drug ID – 进入单独的产品界面

每个产品都有单独的信息界面，并可以点击右上角的tools查看这个国家的source原始渠道及methodology



Therapy View	Yes	Volume		Price Comment	
National Drug ID	W69731001-CANAMED	Volume Units		First Price (LCU)	219.52
Generic Name	RIMEGEPANT	Dose		First Price Date	01-Dec-2022
Drug Geography	Romania	Dose Unit		Time to Pricing	220
ISO Code	RO	Drug Type	Branded	DDD Cost (LCU)	50.31
EMA Brand ID	EMEA/H/C/005725	Parallel Import	No	Regulatory Submission Date	08-Feb-2021
Brand Name	VYDURA	Withdrawn/Not launched	No	First Approval Date	25-Apr-2022
Company (Parent)	Pfizer	Withdrawn/Not launched Comment		Launch Date	
Company (Subsidiary)	Pfizer Europe	Source	Ministry of Health (CANAMED Main List)	Hospital Status	No
ATC Code	N02CD06	Price Date	20-Feb-2025	Orphan Drug Designation	No
Therapy Area / Indication	Migraine	Currency (Local)	RON	Breakthrough Therapy	NA
Defined Daily Dose (DDD)	37.5 MG	Ex-manufacturer Price (LCU)	201.24 →	Authorization Procedure	Centralised
International Drug ID	EU/1/22/1645/001	Wholesale Price (LCU)	221.36 →	Reimbursement Status	NA
Dosage Form	ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER, PVC/OPA/ALU FOIL)	Retail Price (LCU)	270.24 →	Level of Reimbursement	
Strength Value (Number)	75	Price Per Unit (LCU)	100.62	First Reimbursement Date	
Strength Unit	MG	Currency (Converted)	USD	Time to Reimbursement	
Strength (Text)	75 MG	Exchange Rate (LCU to USD)	0.20956	First Price Change Date	01-Jan-2025
Strength Comment	75 MG	Ex-manufacturer Price (USD)	42.17	First Price % Change	-8.33
Number of Units	2	Wholesale Price (USD)	46.39	Other Price (LCU)	
Region	National	Retail Price (USD)	56.63	Other Price (USD)	



Romania为例，包括当地语言官方渠道的每月及每年更新数据，点击即可access原始文档

POLI methodology - Romania

Friday, February 21, 2025 | Methodology

Attachments

CANAMED_monthly_changes CANAMED_yearly PUBCAT_monthly_changes PUBCAT_yearly_changes

PharmOnline International database

Help brochure: Romania

Romanian data is updated using two sources CANAMED and PUBCAT. In Romania, the Ministry of Health (MOH) publishes a **yearly file** containing comprehensiv
CANAMED was last updated on 01 January 2025 (can be found in attached file, dated 19 December 2024, effective from 01 January 2025) and the yearly file of
2023 (can be found in attached file, dated 28 July 2023, effective from 01 August 2023).

Throughout the year, MOH releases **monthly updates** that include modifications, additions of new drugs, and deletions from the yearly file.

The National Catalogue of Medicines (CANAMED) is updated every month and the latest CANAMED file (covering Reference Lists A, B, and Annex 3) is valid from
accessed **here** (**Step 1:** Go to E-monitor on top left, **Step 2:** select the date Feruary 3, 2025 in calendar, **Step 3:** click on Part 1, number 96 file). The Public Cata
quarter. The latest PUBCAT update is valid from 28 January 2025.The file can be accessed **here** (**Step 1:** Go to E-monitor on top left, **Step 2:** select the date Jan
3: click on part 1, number 68 file).

The attached files include the yearly files and monthly files for both CANAMED and PUBCAT.

Methodology

GlobalData POLI uses prices of drugs provided by official sources. The Romanian Ministry of Health is used in Romania.

The scope of drugs included in the database is country-dependent: all drugs for which prices are set, all drugs funded and for which prices are set, or a basket o

In Romania, the basket of drugs includes all prescription drugs on the market.

Price calculations

Source	Ex-manufacturer price	Wholesale price	Retail price, including value-added tax (VAT)
CANAMED - main list	Provided by the source	Provided by the source	Provided by the source
CANAMED - lists A, B & Annex 3	Provided by the source	Estimated by GlobalData	Estimated by GlobalData



1 / 16 − 100% +

MONITORUL OFICIAL AL ROMÂNIEI

Anul 193 (XXXVII) — Nr. 57 — PARTEA I LEGI, DECRETE, HOTĂRÂRI ȘI ALTE ACTE — Joi, 23 ianuarie 2025

SUMAR

Nr. Pagina

ACTE ALE SENATULUI

2. — Hotărâre pentru modificarea Hotărârii Senatului nr. 134/2024 privind aprobarea componenței numerice și nominale a comisiilor permanente ale Senatului 2

DECRETE

13. — Decret privind conferirea Ordinului *Virtutea Militară* 2

14. — Decret privind conferirea Ordinului *Virtutea Militară* 3

15. — Decret privind conferirea Ordinului *Virtutea Militară* în grad de *Ofițer* 3

ACTE ALE ORGANELOR DE SPECIALITATE ALE ADMINISTRAȚIEI PUBLICE CENTRALE

117. — Ordin al ministrului sănătății privind modificarea și completarea anexei nr. 1 la Ordinul ministrului sănătății nr. 5.994/2024 pentru aprobarea prețurilor maximale ale medicamentelor de uz uman, valabile în România, care pot fi utilizate/comercializate de către deținătorii de autorizație de punere pe piață a medicamentelor sau reprezentanții acestora, distribuitorii angro și furnizorii de servicii medicale și medicamente pentru acele medicamente care fac obiectul unei relații contractuale cu Ministerul Sănătății, casele de asigurări de sănătate și/sau direcțiile de sănătate publică județene și a municipiului București, cuprinse în Catalogul național al prețurilor medicamentelor autorizate de punere pe piață în România, a prețurilor de referință generice și a prețurilor de referință inovative 4–6

ACTE ALE ÎNALTEI CURȚI DE CASAȚIE ȘI JUSTIȚIE

Decizia nr. 103 din 25 noiembrie 2024 (Completul pentru dezlegarea unor chestiuni de drept) 7–14

ACTE ALE BĂNCII NAȚIONALE A ROMÂNIEI

5. — Ordin privind publicarea efectuării radierii din Registrul general și din Registrul special Instituții Financiare Nebancare a Societății OTP LEASING ROMANIA IFN — S.A. 15

*

Rectificări 15

每个产品界面还有三种药品价格在特定国家的变化情况，数据追溯up to 10 years







以及同一产品（剂型剂量包装一致 same national ID) 的IRP：即国际参考药价情况，可以看到Romania有13个reference country即定价时参考哪些国家的药品价格，以及10个referrer国家





案例分析：偏头痛药物定价准入分析

回到检索结果表格：**2. 点击Brand Name 进入该产品的品牌界面**



该品牌在全球各国价格及医保情况，若贵司产品与此相似，可以深度参考该药物的商业化战略，包括定价，上市顺序，可触达市场选择，医保获批国家/医保程度， 以及治疗费用计算和HTA影响 – 提供在线计算工具



该品牌在全球各国的三种价格类比：ex-manufacturer price, wholesale, retail price (USD) 以及 lowest publish price, price per strength unit, DDD cost



Drug View

- Availability
- Prices
- Reimbursement
- Launch Sequence
- Therapy Cost & HTA
- Customize Therapy Cost

Insights

- Headline Analysis
- Time to Pricing / Reimbursement
- Time to HTA

- Ask the Expert
- Country Methodology

Rimegepant (Nurtec, Nurtec odt, Vydura) | Prices

My GlobalData Tools

Refine

Your Refinements — Parallel Import: No — Pack Type: Most Common Pack

1 - 25 of 27 Results | Results Analytics | Export

Page 1 of 2 | Previous Next | Go to page 1 | 25 Results

Drug Details			Pricing (Given By the Source / Calculated - Regulated Margins / Calculated - Unregulated Margins)							
Geography	Brand Name	Pack Description	Ex-manufacturer Price (USD)	Wholesale Price (USD)	Retail Price (USD)	Lowest Published Price Type	Lowest Published Price (USD)	Price per Strength Unit (USD)	DDD Cost (USD)	Price Erosion (%)
Switzerland	VYDURA	2 ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER, PVC/OPA/ALU FOIL) 75 MG	56.63		79.95	Ex-Manufacturer	56.63	0.38	14.15	0
Belgium	VYDURA	2 ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER, PVC/OPA/ALU FOIL) 75 MG	54.88	57.18	68.93	Retail	68.93	0.37	13.72	0
Lithuania	VYDURA	2 ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER, PVC/OPA/ALU FOIL) 75 MG	54.88	57.62	69.58	Ex-Manufacturer	54.88	0.37	13.72	0
Luxembourg	VYDURA	2 ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER, PVC/OPA/ALU FOIL) 75 MG	54.88	57.18	66.98	Ex-Manufacturer	54.88	0.37	13.72	0
Bulgaria	VYDURA	2 ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER, PVC/OPA/ALU FOIL) 75 MG	53.47	55.60	76.99	Ex-Manufacturer	53.47	0.36	13.37	0
Slovenia	VYDURA	2 ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER, PVC/OPA/ALU FOIL) 75 MG	48.34	49.40		Wholesale	49.40	0.32	12.08	0
Austria	VYDURA	2 ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER, PVC/OPA/ALU FOIL) 75 MG	47.49	53.43	75.22	Ex-Manufacturer	47.49	0.32	11.87	0
Cyprus	VYDURA	2 ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER, PVC/OPA/ALU FOIL) 75 MG	47.38	48.81	69.19	Retail	69.19	0.32	11.85	0
Portugal	VYDURA	2 ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER, PVC/OPA/ALU FOIL) 75 MG	45.10	48.26	59.49	Retail	59.49	0.30	11.28	0
Estonia	VYDURA	2 ORAL LYOPHILISATE (SINGLE-DOSE, BLISTER,	44.32	45.65	57.11	Retail	57.11	0.29	11.09	0

该品牌在全球各国医保情况



该品牌在全球各国上市的时间及顺序策略



该品牌产品不同国家对应适应症：治疗费用估算包括perfect use vs. wastage，以及分析HTA 对于价格及治疗费用变化的影响

Drug View

- Availability
- Prices
- Reimbursement
- Launch Sequence
- Therapy Cost & HTA
- Customize Therapy Cost

Insights

- Headline Analysis
- Time to Pricing / Reimbursement
- Time to HTA

- Ask the Expert
- Country Methodology

Rimegepant (Nurtec, Nurtec odt, Vydura) | Therapy Cost & HTA

My GlobalData Tools

Refine

Note: for better visibility, the graphs are limited to the first indication(s) approved in Australia, France, Germany, Italy, Japan, Spain, UK, and USA. With the assistance of the Refine Filter option, users can modify the graph to their preferences.

1 - 25 of 39 Results | Results Analytics | Export | Page 1 of 2 | Previous Next | Go to page 1 | 25 Results

Therapy/Drug Details					Therapy Costs (USD)				HTA Details (Positive, Neutral, Negative, Not Yet assessed, NA)			
Therapy Area/Indication	Indication Details	Full Indication	Drug Geography	Indication Approval Date	Monthly - Perfect Use	Annual - Perfect Use	Monthly - With Wastage	Annual - With Wastage	Reimbursement	First Positive Decision Date	HTA Outcome	Comment
Migraine	Acute Mono	For the acute treatment of migraine with or without aura in adults.	United States	27 Feb 2020	3,858.60	46,946.30	3,858.60	46,946.30	NA	25 Feb 2020	Comparable or Incremental (C+)	No vote (no price at the time of meeting), with a discount of 5-15% required for the WAC to fall within the recommende value-based pricing benchmark.
Migraine	Acute Mono	Acute treatment	Austria	25 Apr 2022	712.33	8,666.63	712.33	8,666.63	0%		Not yet assessed	
Migraine	Preventive	Preventive	Austria	25 Apr 2022	356.16	4,333.32	356.16	4,333.32	0%		Not yet assessed	
Migraine	Acute Mono	Acute treatment	Bulgaria	25 Apr 2022	802.08	9,758.62	802.08	9,758.62	0%		Not yet assessed	
Migraine	Preventive	Preventive	Bulgaria	25 Apr 2022	400.96	4,878.34	400.96	4,878.34	0%		Not yet assessed	

案例分析：偏头痛药物定价准入分析

定性分析（独家一手调研）洞察

另外**POLI**分析师团队（全球**100+**）每日发布的独家洞察**INSIGHT**，针对该产品在各国的情况（药价、政策、获批、市场准入**etc.)** 深入分析



案例分析：偏头痛药物定价准入分析

回到检索结果表格：**3. 点击Therapy View: Yes – 进入到每个产品的治疗费用计算**





获批的治疗情况 1： **Preventive**



获批的治疗情况 2： **Acute**

可根据该产品在特定国家的获批适应症情况，分别计算治疗费用，提供在线计算模型，可调整任意影响参数来计算出最符合自家药物情况的**estimated cost**

AI Hub – Pharma

2025 – Pharma Priorities for AVA 在线即时问答

UPDATD



Pharma 2025 Plans:

- ❑ Continue to review existing prompts and create additionall prompts
- ❑ Improve accuracy of sourcing & responses
- ❑ Enhance UX – sharing, custom exports, etc.
- ❑ Ability to use “related links” to pre-filtered IC pages
- ❑ Translation, additional filtering
- ❑ Develop team culture for “AI First” approach





		Level of Impact	Type of Impact
		High	↑↑↑
		Medium	↑↑↑
2025	Launch of biosimilar versions of Benlysta. Patent expiry of Benlysta	Medium	↓↓
2026	Launch of Gazyvero (obinutuzumab)	High	↑↑↑
2027	Launch of Cosentyx	High	↑↑
2027	Launch of Sotyktu (deucravacitinib)	High	↑↑↑
2027	Launch of Ataciept	Medium	↑↑
2027	Launch of Ifitifilimab	High	↑↑
2028	Launch of Ianalumab	High	↑↑

pan, 2021–2031
Source: GlobalData © GlobalData

AI HUB: Prompt Cards 智能维度分析

- Prompt cards, curated and validated by expert analysts, offer a series of guided workflows tailored to various specific use cases :
  - Competitor Intelligence
  - Sales Intelligence
  - Market Intelligence
  - Strategic Intelligence
  - Innovation Intelligence
- AI HUB offers 24 unique Prompt Cards
- Each prompt cards contains sub cards to provide in-depth autogenerated insight and analytics.
- Readily downloadable reports with Key tables, Charts and insights.



Case Study – Company Deal Strategy

仅仅输入任何一个公司名称，就可以一键自动生成公司的交易战略总结报告



Case Study: Innovation Landscape

仅仅输入任意一个靶点/机制名称，就可以一键自动生成靶点开发进展总结报告，并关联所有数据库中引用渠道Sources



Lead Sheet Intelligence Module

Lead Sheet/Sales Intelligence – 2025 Snapshot

Lead Sheet will become new Sales Intelligence Solution. Nothing will be lost from Lead Sheet existing data & functionality – only enhancements. Users will have the ability to find and prioritise the best prospects, create account plans and sales enablement content, and engage with the right people at the right moment with right information.

PLAN

Strategize your sales approach with data-driven insights.



ENABLE

Tailored sales assets that align and connect with your audience's needs.

TARGET

Identify and prioritize high-potential prospects effortlessly.

ENGAGE

Stay informed with real-time insights for smarter engagement.

Buying Signals (Leads)
Buying Signals on current and future Clinical Trials events, Deals, Regulatory filings and much more
(Drugs Intelligence subscription required)

Market Planner/Updates
Identify and prioritize markets and understand key trends

Catalyst Calendar
~60,000 Catalysts covering Clinical Trials, Regulatory and IP events

Ideal Customer Profiler/ Territory Prioritizer
Generate list of target companies and prioritize

Contacts
~390,000 Contacts, including C-level, Scientific, Clinical Operations, Commercial etc.

Company Enablement/ Industry Enablement
Tailored sales assets that align and connect with audience needs

Catalyst Monitor Reports
Quarterly reports covering the most material catalysts expected in the next quarter with Insights journalist coverage



**This can be complemented with API subscriptions for CRM Integration*

Fundamental Support to CXOs

Drugs Intelligence – 2024 Snapshot

Global coverage of pipeline drugs, deals, news, deals and companies; marketed drugs across 20+ countries including the US, Europe, LATAM and Asia. Updated daily.

Pipeline Drugs
~93,600 pharma and biologics, preclinical to pre-registration

Marketed Drugs
~ 169,500 novel, biologic, biosimilar and generics

Regulatory Milestones Tracker
Patent Expiry for ~10,500 drugs and ~ 6,500 review designations

Drug Sales & Consensus Forecast
Historical sales from 2000; eight-year analyst consensus forecast

PharmSource
Leading source for global contract manufacturing intelligence

↑

Assess competitive drug development landscape

Companies
Over 143,000 companies profiled including locations and subsidiaries

Deals
1.4M Deals including M&A, licensing, financings and grants

News
Press releases and proprietary articles covering latest events and trends – over 500,000 articles

↑

Understand companies and key activities occurring across the pharma industry in real-time

Financials
Income statement, balance sheet and cash flow statements, plus financial ratios

NPV & rNPV
16-year sales forecasts; change expiry and growth assumptions

Integrated Export
Single search and export from multiple databases

Likelihood of Approval
Predict likelihood of approval and phase transition success rate of a drug - ~20,000 individual LOAs

↑

Take advantage of Analytical Tools on Pharma Intelligence Center



药物开发
公司尽调
财务状况
生产商信息
药物监管
临床成功率

Exclusive Sources to CXOs

Lead Sheet – 2024 Snapshot

A user-friendly business development tool that pulls new, daily opportunity triggers across the intelligence center databases that helps users identify when to reach out to certain companies and the key decision makers at those companies that may need services.

Lead Sheet
Leads on current and future Clinical Trials events, Deals, Regulatory filings and much more
(Drugs Intelligence subscription required)

Catalyst Calendar
~90,000 Catalysts covering Clinical Trials, Regulatory and IP events

Contacts
~400,000 Contacts, including C-level, Scientific, Clinical Operations, Commercial etc.

Catalyst Monitor Reports
Monthly reports covering the most material catalysts expected in the next month with Insights journalist coverage

↑

Get Leads and Contacts for your Business Development

**This can be complimented with API subscriptions for CRM Integration*

自定义目标市场
业务线索精准推送
关键联系人信息
会议潜在客户追踪
独家业务机会邀请

Outsourcing Insights - Results





Lead Sheet Contact Search



Lead Sheet: actionable leads generated by catalysts and events from clinical and commercial perspectives – approach and pitch via Contacts to find right ppl

FEATURE

Lead Sheet is a business development tool that will help you to optimise sales efficiently by showing you which prospective account to target, when and why to target them and who to reach out to for each account.

BENEFITS

- Robust Leads: Discover 20+ types of leads, some proprietary, which have been verified by research teams.
- Key decision-makers: Gain unlimited access to verified email of C-Level and Executive leads in 20 departments.
- Prospective accounts: Benefit from benchmarking metrics, CRO and CMO relationships, new companies added daily and key account uploads.
- Customizable territories: Customize by geography, therapeutic area and company type/industry

New Feature – New Lead Types

- Growing companies leads are a good signal for many existing clients and prospects in staffing/recruitment
  - New Office/Building Location
  - Increase in Hiring
- Conference attendance is a very valuable lead type for all suppliers and GD has access to great data here



Contacts – fully integrated with other databases to generate prospects within one click





Advanced watchlist can also be applied as a searchable filter in Contacts Database – to generate all contacts from a conference delegate list

Catalyst Calendar – integrated into Drug Profile to see all upcoming events of a company or indication or drug in a period of time

FEATURE

Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.

BENEFITS

- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)

VALUE

- Proactively evaluate companies and catalyst impacts
- Stay ahead of the competition & improve corporate planning
- Bolster business development with timely opportunities.



Proprietary Analysis to CXOs

产业格局
机会捕捉
外包服务合同
并购分析
独家业务邀请

PharmSource – Analysis

Released by in-house analysts monthly, quarterly, and yearly designated to Service Providers

GlobalData.

Report Code: GDPS0051MAR November 2024

Contract Pharmaceutical Dose Manufacturing Industry: Composition, Size, Market Share, and Outlook – 2024 Edition

Inside:
Executive Summary
Players
Trends
Industry Analysis
Value Chain
Companies
Appendix
About the Authors

Related Reports:
M&A in the Contract Manufacturing Industry: Implications and Outlook – 2024 Edition
New Drug Approvals and Their Contract Manufacture: 2024 Edition
Global AI Trends in Pharmaceutical Manufacturing
Bio/Pharmaceutical Outsourcing Report – October 2024

GlobalData.

Report Code: GDPS0049MAR April 2024

New Drug Approvals and Their Contract Manufacture: 2024 Edition

Inside:
Executive Summary
Players
Technology Briefing
Trends
Industry Analysis
Value Chain
Companies
Appendix
About the Authors

Related Reports:
Global AI Trends in Pharmaceutical Manufacturing
Contract Pharmaceutical Dose Manufacturing Industry: Composition, Size, Market Share, and Outlook – 2024 Edition
M&A in the Contract Manufacturing Industry: Implications and Outlook – 2024
Bio/Pharmaceutical Outsourcing Report – March 2024

GlobalData.

Report Code: GDPS0050MAR June 2024

M&A in the Contract Manufacturing Industry: Implications and Outlook - 2024 Edition

Inside:
Executive Summary
Players
Technology Briefing
Trends
Industry Analysis
Value Chain
Companies
Appendix
About the Authors

Related Reports:
New Drug Approvals and Their Contract Manufacture: 2024 Edition
Global AI Trends in Pharmaceutical Manufacturing
M&A in the Contract Manufacturing Industry: Implications and Outlook – 2024
Bio/Pharmaceutical Outsourcing Report – July 2024

GlobalData.

October 2024

PharmSource, a GlobalData Product

Report Code: GDPA296

Contract Manufacturing: Opportunities and Threats – October 2024

Contract Manufacturing: Opportunities and Threats identifies contract manufacturing organizations (CMOs) that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

Table 1: Contract manufacturing: opportunities and threats – potentially positive

Contractor	Biopharma Company	Event Description	Product*	Relationship
Amsilgma SpA	Windtree Therapeutics Inc	Positive Phase II top-line results	istaroxime	Small mol. API
Almac Group Ltd	Pharmaand GmbH	NICE approval	Rubraca	Solid dose manufacture & packaging
	Janssen-Cilag International NV	EMA approval	Yuvaxxi	Solid dose packaging
	Ipsen SA	EMA expanded indications	karyfanda	Solid dose manufacture & packaging
AstraZeneca Plc	Merck Sharp & Dohme Corp	FDA expanded indications	Keytruda	Reviewer API

GlobalData.

October 2024

PharmSource, a GlobalData Product

Report Code: GDPA298

October Quarterly Contract Manufacturing Mergers, Acquisitions, and Financing – Q4 2024

Mergers, Acquisitions, and Financing identifies deals relevant to the bio/pharmaceutical manufacturing space that were announced during the quarter to date. This includes 100% of company acquisitions and purchases of business units or facilities.

Table 1: Mergers, acquisitions, and financing – Q4 2024

Investor/acquirer	Target/vendor	Deal	Deal subtype	Deal value ($M)

GlobalData.

October 2024

PharmSource, a GlobalData Product

Report Code: GDPA297

Contract Service Agreements – October 2024

Contract Service Agreements identifies deals struck between CMOs and bio/pharma clients for services including API manufacture, dosage form manufacture, packaging, and analytical services.

Table 1: Contract service agreements

Contractor	Biopharma company	Deal	Drug(s)	Number of drug(s)	Molecule type(s)
Andelyn Biosciences Inc	Hubble Therapeutics Inc	Hubble Therapeutics Enters API Manufacturing Agreement with Andelyn Biosciences for AAV	HUB-101	1	Gene therapy
BioCina Pty Ltd	Centivax Inc	Centivax Enters API Manufacturing Agreement with BioCina for Cent-Flu	Cent-Flu	1	mRNA vaccine
BioCina Pty Ltd	EnGeneIC Ltd	EnGeneIC Enters Manufacturing Agreement with BioCina for EnGeneIC Dream Vector	EE DVD-682	1	Small molecule
Cellgenix Biosciences	Mongoose Bio Inc	Mongoose Bio Enters API Manufacturing Agreement with Cellgenix Biosciences for MGB-001	MGB-001	1	Gene-modified cell therapy

Client list: CXO (mainly CDMO & CRO) who have focus on overseas markets

PIC (Drugs/Trials + LS)	Thought leadership & Media	Custom Support
• BD • MRKT	• MRKT • Strategy	• Strategy • C-level

Integration with Sales Intelligence: buying signals from your targeted territories



CRO案例分析

临床运营
项目管理
报价方案支持
可行性分析

Trials Intelligence - Overview

	Description
Clinical Trials	Clinical Trials Database is a comprehensive and fully integrated database of globally conducted clinical trials since 1995.
Investigators	A comprehensive repository of global specialty-based clinical trial investigators.
Trial Sites	Trial Sites database is a comprehensive resource for trial sites associated with the clinical trials conducted globally.
Site Coordinators	A repository of global trial site coordinators sourced from numerous government/non-government sites worldwide alongside clinical research publications, conferences etc.
Enrollment	Enrollment Data module offers the user with trial enrollment and trial timing information for clinical trials conducted globally.
Feasibility Planner	Feasibility Planner Module offers users a unique platform to perform feasibility planning for a clinical trial.
Biomarkers	Provides the information on biomarkers used in human clinical research.

Offering Insights

- Trials Intelligence offering allows clinical operations professionals to make more confident decisions around trial planning, site selection, investigator identification and provide much more comprehensive clinical trial related information with detailed insights.
- **Investigator** profile provides a complete view of Investigator overview, performance indicators, clinical trials, trial sites, investigator details, designation details, education details, network, and contact details.
- **Site coordinators** advanced search allows user to combine the search with attributes from Site Coordinators, Sites, Clinical Trials and Drugs for more accurate results.
- **Feasibility Planner**: A fully integrated analytical tool, that helps in trial planning, benchmarking, and assessment of recommended geography, sites and investigators.
- **Biomarkers** database provides the information on biomarkers used in human clinical research. Information is manually curated from clinical trials and scientific literature.
- Use "**Integrated Results Summary**" to get the stats for Drugs, Companies, Investigators, Trial Sites and Site Coordinators associated with the clinical trials retrieved in the search.

2024 New Feature – **Clinical Trial Cost**

Feasibility Planner - Use Case 1

Top Key Insights on Upcoming Refractory Chronic Lymphocytic Leukemia (CLL) Trial



Feasibility Planner - Use Case 2

Insights on Project Timelines and Enrollment Goals for Upcoming Trial Program



Thought Leadership | 市场推广白皮书

Case Study: Global Trends in Clinical Trials & Thought Leadership

Client: Leading CRO

SITUATION

Our client, a leading CRO Marketing team wanted support with their content generation and to become a thought leader in the field. They specifically needed analysis of the evolution of clinical trials activity, sponsors and new technologies that could impact pharmaceutical clinical development in the APAC region.

SOLUTION

- GlobalData Consultants have created multiple corporate presentations, competitive landscapes, and White Papers, now publicly available, on a plethora of topics – including but not limited to:
  - Project 1: Evolution of CT landscape in the APAC region compared to the US and EU5
  - Project 2: China Biotech Landscape and strategies for approval
  - Project 3: State of the Biopharma Industry: where do the opportunities lie?
  - Project 4: Regulation in the US: Simplifying the complex
- PMR with clients own internal (n=5) experts and external (n=7) KOL experts
- Comprehensive insight and analysis during the write up across 3 white papers

OUTCOME

- GlobalData is an embedded partner with this client, providing business insights and strategic direction support to enhance their commercial effectiveness and positioning



Navigating the FDA Approval Processes: Capitalize on Regulatory Expertise to Simplify the Complex



Pharmaceutical Technology | GlobalData Media 全球研发媒体平台

Media brand owned by GlobalData | Free Digital Pharma Magazine in August – click here.

Jasper Morley: Johnson & Johnson to dominate BiTE market by 2030, forecasts GlobalData
Shireen Mohammad: NewAmsterdam's obicetrapib holds potential to become first CETP inhibitor to advance to clinical practice, says GlobalData
Yixuan Zhang: RCC diagnosed incident cases to reach 230,000 in 8MM by 2033, forecasts GlobalData
Kajal Jaddoo: SC0062 trial results highlight BioCity's potential to differentiate in kidney disease space, says GlobalData
Eleni Tokali: Roche's Vabysmo and Regeneron's Eylea HD to dominate anti-VEGF-A market by 2030, forecasts GlobalData
Sachin Gharat: Majority of UK physicians see continued rise in telemedicine usage, reveals GlobalData
Stephanie Kurdach: Phase III post-marketing commitment study data paves way for usage of Paratek's Nuzyra in other indications, says GlobalData
Sravani Meka: Pipeline Power: Sionna's AbbVie Deal Could Redefine CF Therapeutics
Fiona Chisholm: Gilead's lenacapavir holds greater potential in reducing HIV incidence than currently marketed drugs, says GlobalData
Christie Wong: Spinal muscular atrophy market across 7MM to grow to $3 billion by 2033, forecasts GlobalData
Adeleke Badejo: AbbVie's Humira loss of exclusivity a missed opportunity for competitors, says GlobalData
Suneedh Manthri: Diagnosed prevalent cases of chronic kidney disease to reach 22.97 million across 7MM in 2033, predicts GlobalData
Lorraine Palmer: Synergistic safety profile could increase sublingual apomorphine competitiveness, says GlobalData
Loraine Palmer: Opicapone demonstrates efficacy in real-world clinical practice, says GlobalData
Filippos Maniatis: Prioritized investments from pharma companies shaping competitive pipeline landscape of bronchiectasis, says GlobalData
Lorraine Palmer: Safinamide outperforms rasagiline in efficacy, cost-efficacy, and forecasted sales, says GlobalData
Pippa Salter: Ajovy benefits diminish with migraine treatment cessation and re-initiation, says GlobalData
Erela Dana: Healey platform data to pave phase III path for Prilenia's pridopidine, says GlobalData
Jos Opdenakker: VNS and cenobamate combo therapy success paves way for cenobamate monotherapy, says GlobalData
Jos Opdenakker: Rituximab's specificity highlights need for broader mAb therapies for myasthenia gravis, says GlobalData
Erela Dana: Preventative treatment of chronic migraine will continue to evolve in short-term with anti-CGRP mAbs effectiveness, says GlobalData
Pippa Salter: Benefits of early migraine treatment clear but implementation remains challenging, says GlobalData
Eleni Tokali: Leqvio and Repatha to spearhead lipid-modifying agents market resurgence, says GlobalData
Asiyah Nawab: EMA approval of Sanofi/Regeneron's Dupixent fills biologic gap in COPD, says GlobalData
Philippa Salter: Eli Lilly's Kisunla approval to heat up competition in the Alzheimer's market, says GlobalData
Shireen Mohammad: Female infertility market across 7MM to grow to $2.3 billion by 2033, forecasts GlobalData
Bharati Prabhakar: Total prevalent cases of female infertility to decrease at 0.4% AGR in 7MM during 2023-33, forecasts GlobalData
Momna Ali: Amylyx looks to cover financial gap left by Relyvrio with avexitide deal, says GlobalData
Sravni Meka: Asthma inhaler price cap in US may help pharma companies to secure more loyal customer base, says GlobalData

Clinical Trial Arena | GlobalData Media 全球临床媒体平台

Media brand owned by GlobalData | Our clinical partners click here

TERUMO BLOOD AND CELL TECHNOLOGIES

Optimizing Cell & Gene Therapy Processes

Partner Content

Navigating the challenges of bringing cell and gene therapies to market

The understanding of cell therapies is rapidly improving, but there remain significant challenges in getting new cell and gene therapies onto the market. We'll explore how careful navigation of these challenges, as well as their solutions, can help ensure patients receive essential treatments without delay.



Partner Content

T-cell manufacturing: When is the right time to automate?



Partner Content

How cell and gene therapy are evolving

Partner Content

Harnessing the power of cell and gene therapy in oncology

Partner Content

Quality versus quantity in T-cell production: Why it doesn't have to be a trade-off

NT NOVOTECH

Accelerating Clinical Trials

Partner Content

Chronic Lymphocytic Leukaemia: the global clinical trials landscape in 2024

A new Novotech report outlines developing treatments for this cancer, which affects over 121,000 people worldwide. Ongoing research holds transformative potential for patients.



Partner Content

Non-small cell lung cancer: the global clinical trials landscape 2024

BAP Pharma

Trusted clinical trial packaging services

Partner Content

Medicines access: Unlocking the immense potential in cell and gene therapy

Despite several ground-breaking developments, pharmaceutical and biotech companies are often reluctant or unable to invest in cell and gene therapy. Here, we discuss the key challenges to access and how the potential of these innovative treatments can be unlocked.



Partner Content

Harnessing the untapped potential of medicines access

Partner Content

Overcoming regulatory issues with investigational medicinal product labelling

Features

Running low on comparators: navigating drug shortages in oncology clinical trials

OXIMIO

The next chapter of clinical trial services

Partner Content

Four key trends in the clinical trial supply chain

Clinical trial supply chains have experienced significant changes in recent years. In the aftermath of the global pandemic, we identify the four key trends in the clinical supply chain and new locations are sought globally.

Partner Content

The growth of clinical trials in Africa

Partner Content

The growing uses of medicinal cannabis

trialbee

The new era of global patient recruitment

Partner Content

How to improve referral to consent ratios with Patient Recruitment Platforms (PRPs)

A panel of industry experts recently came together to discuss the benefits of real-time data collection through PRPs in clinical trials. What did they find? Clinical Trials Arena breaks it down for you.

Fi Forrest

Partner Content

PRPs: What is a Patient Recruitment Platform (and why do you need one)?

Partner Content

Is patient recruitment out of control?

News

AACR publishes a guide to improving diversity in US clinical trials

PM TRIALS

Improving decentralized trials with mobile research nursing

Partner Content

Clinical trial access in the US: Where are today's trials missing?

We use the latest clinical trial data to map out active site locations and understand how healthcare deserts are affecting clinical trial access in the United States, and how this can be addressed.

Miranda McLaren

Partner Content

Decentralized Clinical Trials for older adults: Mobile research trends and recommendations

Partner Content

Mobile visits are critical for the decentralization of rare disease research

Arena International Event| GlobalData Event 全球临床及供应链会议



19th Annual Outsourcing in Clinical Trials & Clinical Trial Supply East Asia 2024

19th Outsourcing in Clinical Trials & Clinical Trial Supply East Asia 2024

3-4 December 2024, Seoul, South Korea

11th Annual Clinical Trials in Oncology Europe 2024 | Testimonials

11th Annual Clinical Trials in Oncology Europe 2024

3-4 December 2024, Munich, Germany